-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WHGKdK8IXOBLs6XxQsAR5VQUjUkCN1fwIhijHxQV38bL8K5+uvGQZSz7AM2LkvMc
 umI2AjtSycOoQ3nxfpELTQ==

<SEC-DOCUMENT>0001144204-07-001984.txt : 20070117
<SEC-HEADER>0001144204-07-001984.hdr.sgml : 20070117
<ACCEPTANCE-DATETIME>20070116200903
ACCESSION NUMBER:		0001144204-07-001984
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070116
FILED AS OF DATE:		20070117
DATE AS OF CHANGE:		20070116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		07533343

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT WEIZMANN BUILDING 3
		CITY:			REHOVOT76100 ISRAEL
		STATE:			L3

	MAIL ADDRESS:	
		STREET 1:		KIRYAT WEIZMANN BUILDING 3
		CITY:			REHOVOT76100 ISRAEL
		STATE:			L3
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v062635_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>v062635</div>
    <div>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
    </div>
    <div>
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      January 16, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>750
      Lexington Avenue, 20</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>th</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      Floor</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>New
      York, New York 10022</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F&#160;<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): <font style="FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): <font style="FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes&#160;&#160;<font style="FONT-FAMILY: Wingdings">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
<font style="FONT-FAMILY: Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="logo.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Biopharmaceuticals Announces the In-Licensing of Bicifadine - A Late-Stage
      Clinical Compound for the Treatment of Neuropathic Pain</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NEW
      YORK,
      NEW YORK, 16 January 2007 - XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, LSE:
      XTL,
      TASE: XTL) announced today that, through a wholly-owned subsidiary, it has
      signed an agreement with DOV Pharmaceutical, Inc. (PS: DOVP.PK) to in-license
      the worldwide rights for Bicifadine, a serotonin and norepinephrine reuptake
      inhibitor (SNRI).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      intends to develop Bicifadine for the treatment of neuropathic pain - a chronic
      condition resulting from damage to peripheral nerves. With 15 million people
      suffering from neuropathic pain in the United States alone, and limited
      treatment options available, neuropathic pain represents a significant unmet
      medical need. According to Datamonitor, the market for neuropathic pain drugs
      is
      expected to grow from $1.8 billion in 2005 to $5.5 billion by 2015.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bicifadine
      is a serotonin and norepinephrine reuptake inhibitor (SNRI). Other members
      of
      the SNRI class include Cymbalta&#174; (approved for depression and neuropathic pain),
      and Effexor&#174; (approved only for depression). Both Cymbalta&#174; and Effexor&#174; have
      been shown to be efficacious in neuropathic pain. Activity on norepinephrine
      reuptake is thought to be necessary for anti-depressants to be effective in
      neuropathic pain. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Compared
      to the currently approved SNRI&#8217;s, Bicifadine has a unique ratio of serotonin
      versus norepinephrine reuptake inhibition, which is weighted toward
      norepinephrine reuptake inhibition, providing a strong scientific rationale
      for
      using Bicifadine for the treatment neuropathic pain indications.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bicifadine
      has been tested extensively in over 15 clinical trials involving over 3,000
      patients, and has been shown to be safe and generally well tolerated. Bicifadine
      was evaluated in various pain indications, including two large, randomized
      clinical trials (n=750 and n=540) in patients suffering from acute
      (non-neuropathic) pain, where Bicifadine demonstrated statistically significant
      efficacy.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dr.
      Christine Sang, Director of Translational Pain Research at the Brigham and
      Women&#8217;s Hospital, Harvard Medical School, commented, &#8220;Neuropathic pain continues
      to be an area of growing unmet medical need, and I believe that Bicifadine
      represents an exciting potential treatment option. Clinical data clearly support
      the role of SNRI&#8217;s for the treatment of neuropathic pain. Based on its mechanism
      of action that includes a unique ratio of serotonin versus norepinephrine
      reuptake inhibition, the demonstrated effect of other SNRI&#8217;s in this disease
      area, and the activity it has demonstrated in acute pain studies, I have a
      high
      degree of confidence that Bicifadine could be successfully developed as a
      treatment for neuropathic pain.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, XTL&#8217;s Chief Executive Officer, commented, &#8220;This is a very important
      event for XTL, as this in-license transforms us immediately into a late-stage
      development company. It is rare to come across an opportunity such as
      Bicifadine, a drug candidate that addresses a multi-billion dollar market,
      in a
      class with a proven mechanism of action, and with an established safety profile
      and clear evidence of activity in the treatment of pain.&#8221; Mr. Bentsur added, &#8220;By
      re-directing the development of Bicifadine away from the novel indications
      in
      acute and chronic pain toward a proven area of efficacy of SNRI&#8217;s in the
      treatment of neuropathic pain, we believe we can be the second approved SNRI
      for
      neuropathic pain, offering a differentiated efficacy and possibly safety profile
      based on the drug&#8217;s emphasis on norepinephrine reuptake inhibition. We are
      excited to bring Bicifadine on board as our lead compound.&#8221; </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      accordance with the terms of the license agreement, XTL will make an up-front
      payment of $7.5 million in cash. In addition, XTL will make milestone payments
      of up to $126.5 million, in cash and/or XTL ordinary shares over the life of
      the
      license, of which up to $115 million will be due upon or post approval of the
      product. XTL is also obligated to pay royalties on net sales of the product
      to
      DOV. In addition, the Company has committed to pay a transaction advisory fee
      in
      the form of stock appreciation rights in the amount equivalent to 3% of the
      Company's current fully diluted ordinary shares, vesting after one year of
      the
      close of the transaction, and 7% of the Company's current fully diluted ordinary
      shares, vesting following successful Phase 3 clinical trial results or the
      acquisition of XTL. Payment of the stock appreciation rights by XTL can be
      satisfied, at XTL&#8217;s discretion, in cash and/or by issuance of the Company&#8217;s
      ordinary shares. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      BICIFADINE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bicifadine
      is a serotonin and norepinephrine reuptake inhibitor (SNRI) being developed
      by
      XTL for the treatment of neuropathic pain. Bicifadine was licensed by XTL from
      DOV Pharmaceutical, which originally licensed it from Wyeth
      Pharmaceuticals.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Four
      Phase 1 clinical trials and 14 Phase 2 clinical trials involving more than
      1,000
      patients were conducted by Wyeth or DOV with an IR (immediate release)
      formulation of Bicifadine. In five exploratory double-blind, placebo-controlled
      Phase 2 clinical trials of the IR formulation conducted by Wyeth, Bicifadine
      demonstrated a statistically significant reduction in pain versus placebo,
      in
      some cases with an outcome suggesting it might be comparable to or better than
      positive controls such as codeine. In addition to these trials with the IR
      formulation, eight Phase 1 clinical trials using the SR (sustained release)
      formulation have been conducted, a formulation that permits less frequent daily
      dosing, improves tolerability and for which patents have been filed. It is
      intended that the SR formulation will be used in future clinical development
      and
      for commercial use. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      two
      additional and larger (n=750 and n=540) single-dose, double-blind,
      placebo-controlled clinical trials with Bicifadine in the treatment of moderate
      to severe post-surgical acute dental pain, Bicifadine produced a highly
      statistically significant, dose-related reduction in pain compared to placebo,
      and which was comparable to a positive control arm (codeine or Tramadol). Both
      trials demonstrated Bicifadine to be safe and generally well-tolerated without
      producing any serious adverse events.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      a
      Phase 3 double-blind, placebo-controlled, clinical trial (n=325) with Bicifadine
      in the treatment of moderate to severe acute pain following bunionectomy
      surgery, statistically significant increases in analgesia were measured as
      early
      as 30 minutes after administration and these effects were sustained for the
      balance of the eight-hour measurement period. In this study, Bicifadine was
      safe
      and generally well-tolerated. The complete assessment of the analgesic action
      of
      Bicifadine under repeat dosing conditions could not be fully elucidated due
      to
      the high level of &#8220;rescue&#8221; analgesic medication used in both the placebo and
      active drug groups.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Due
      to
      the highly competitive nature of the market for acute pain drugs, and the FDA
      requirement to complete two repeat-dosing clinical trials in two different
      acute
      pain indications, no further studies in acute pain are planned.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bicifadine
      has been further evaluated in three Phase 3 trials in Chronic Lower Back Pain
      (CLBP). The primary efficacy endpoint in these trials was the change in pain
      severity rating score between baseline and the end of dosing. In these trials,
      Bicifadine was safe and generally well tolerated, but did not show a
      statistically significant effect relative to placebo on the primary endpoint
      of
      the study at any of the doses tested.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      believes that the failure of Bicifadine in the CLBP trials was a result of
      the
      inherent heterogeneity of the studied patient population (i.e. the varying
      causes of CLBP pain), uncontrolled physical activities in what is largely an
      activity-dependent pain indication, and a high placebo response.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      believes that by re-directing the development of Bicifadine away from the novel
      indications in acute and chronic pain toward a proven area of efficacy of SNRI&#8217;s
      in the treatment of neuropathic pain, Bicifadine could be successfully developed
      to be the second approved SNRI for neuropathic pain, offering a differentiated
      efficacy and possibly safety profile based on the drug&#8217;s emphasis on
      norepinephrine reuptake inhibition.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the acquisition, development and
      commercialization of therapeutics for the treatment of neuropathic pain and
      hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine
      reuptake inhibitor, for the treatment of neuropathic pain. In addition, XTL
      is
      developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the
      hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1 clinical trial
      in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a
      combination of two monoclonal antibodies against the hepatitis C virus -
      presently in Phase 1 clinical trials in patients with chronic hepatitis C.
      XTL&#8217;s
      hepatitis C pipeline also includes several families of pre-clinical hepatitis
      C
      small molecule inhibitors. XTL also has an active in-licensing and acquisition
      program designed to identify and acquire additional drug candidates. XTL is
      publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ:
      XTLB; LSE: XTL; TASE: XTL). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Contact:</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(212)-531-5960 </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Cautionary
      Statement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Some
      of the statements included in this press release, particularly those
      anticipating future clinical and business prospects for our clinical compound
      for neuropathic pain, Bicifadine, operating strategies and similar matters,
      may
      be forward-looking statements that involve a number of risks and uncertainties.
      For those statements, we claim the protection of the safe harbor for
      forward-looking statements contained in the Private Securities Litigation Reform
      Act of 1995. Among the factors that could cause our actual results to differ
      materially are the following: our ability to successfully complete
      cost-effective clinical trials for the drug candidates in our pipeline which
      would affect our ability to continue to fund our operations with our available
      cash reserves, our ability to meet anticipated development timelines for the
      drug candidates in our pipeline due to recruitment, clinical trial results,
      manufacturing capabilities or other factors; and other risk factors identified
      from time to time in our reports filed with the Securities and Exchange
      Commission and the London Stock Exchange, including our annual report on Form
      20-F filed with the Securities and Exchange Commission on May 25, 2006. Any
      forward-looking statements set forth in this press release speak only as of
      the
      date of this press release. We do not intend to update any of these
      forward-looking statements to reflect events or circumstances that occur after
      the date hereof. This press release and prior releases are available at
      http://www.xtlbio.com. The information in our website is not incorporated by
      reference into this press release and is included as an inactive textual
      reference only. </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
              BIOPHARMACEUTICALS LTD.</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:&#160;January
              16, 2007</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/
              Ron
              Bentsur</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Ron
              Bentsur</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Executive Officer</font></div>
            </td>
          </tr>

      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0`\17AI9@``24DJ``@````!`&F'!``!
M````&@`````````!`(:2`@`'````+`````````!704Y',@(``/_;`$,`"`8&
M!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<'"`D+B<@(BPC'!PH-RDL
M,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-&#(A'"$R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_``!$(
M`$T`W0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)
M"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1
MH0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-4
M55976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U
M]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"
M`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2
M\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D
M969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2U
MMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,
M`P$``A$#$0`_`/?Z***`"BFDX&:^7/&'B[4?%>JSR2W$HT]7_P!&MONJJKNV
MLR_\]-K?,W^U_=K?#T)5FTNAC6K*DM3ZEHKR+X0^,;_59KK1M5N9;IX8_M$$
MTGS-MW;65F_BY9=O_`O]FO6\?E6=6FZ<G%E4ZBJ1NAU%%%0:!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`F>*\0^*L>N^']7BU#3
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M[ONKN9C\V[AC7C9\7>)<9/B'5O\`P.D_^*KI_BMXHDUKQ(^EV\S#3].;R_+Z
M+),OWF^[_#]W_@/R_>JC\-O"C^)?$L4DT:MI]DZRW.YAS][:FW'S;BOS?[.?
M6IHQ4*;JU=6QU&Y34*>QUL2>)-+^$.IZS?:SJ+7EV+>6`F\8M#%YB[=K?PLV
MYMWS?=VUYQ_PEWB7'_(P:M_X'2?_`!5?3VK:58ZYILNG7\/G6TNWS(]Q7.UM
MPY'N*YW_`(55X+_Z`W_DU-_\56%+%4DGSQU;OT-ZN'F[*#T]3P/_`(2[Q+_T
M,&K?^!TG_P`51_PEWB7_`*&#5O\`P.D_^*KT/XI>#/#_`(<\-6MWI6G^1/)>
M+"S>=(WR^7(W\3?[(KR,UW4I4ZL>91_`X:BJ4Y<K?XFS_P`)=XE_Z&#5O_`Z
M3_XJC_A+O$O_`$,&K?\`@=)_\57OO_"J_!>/^0-_Y-3?_%5R_C[P#X9T/P3J
M.HZ=IGDW47E^7()Y&V[I%7HS>C5SQQ5"4E%1W\D;O#58Q<G+\6>5?\)=XEQ_
MR,&K?^!TG_Q5?2OA:5YO"6CS3NTDTEE`\DCG+,QC7D^]?*/:OJ_P?_R).A?]
M@^W_`/1:U&/C%*-D7@Y-R=V;=(?NGZ4M(WW3]*\T]!['`W=]=K?3J+J<*LI4
M`.?6NY&`!U_I7GUY_P`?MQ_UT?\`G7=3WD%E$'N)%1<=^IKOQ4-(**W/DL@K
MVJ8B566B:W>V_<NT5BP>(["?Y2SQ'MO7%:,<\<T6]'5E]5;-<<J<X?$K'TM#
M&8?$*]*:EZ/]-RAKCM#I,DD;F-E(PP..XJCX;GN+AK@32NX&W!=L^M;LD\<4
M6^2157U+8I(KN&=3Y,J/CKL;=6D9VI./+\SBJX3FQT*_M;65N7OOY^?8M44W
MM5&XU6SM&V2SJK>F,G]*RC%R=DCT:M:G2CS5))+S=C0HK'@\1:?-C<YC+'&'
M&*U0P89&"/:G*$H.TE8FABJ&(5Z,U+T'T445!N%%%%`'D'Q>\(_:[)/$&GVV
M^YMR5O?+7YI(\<2-_NX_N_=;^ZM>,1326\T<T$C1S1LK1R1MM96_O+7U1XKU
MFPT3PW>7>H")X3&T:PR])V*G$?\`P+I7RGC`KUL#.4H.+V1Y>+BHS31-:6TU
M]>06=LF^>>188QNV[F9MJU]0^#_#\?AGPU:Z:I4RJ-T\@_Y:2'[Q^ZN>?E'^
MRJU\Z>$M?;PSXCM-4$:/'&VV96C5F\MOO;?[K;?\[=U?45G=Q7]C;WEL^^"X
MC6:,XQN5AN6LLPE/W5T-,'%:OJ7****\X]`\Q^./_(E6?_80C_\`1<E>!FO?
M/CC_`,B59_\`80C_`/1<E>!FO8P/\%GDXO\`C'V37%_%;_DFVJ_]L?\`T<E=
MI7%_%;_DFVJ_]L?_`$<E>53_`(D3TJO\-GS5VKZO\'_\B3H7_8/M_P#T6M?*
M':OJ_P`'_P#(DZ%_V#[?_P!%K7H9AM$X<#\4C;I&^Z?I2TA^Z?I7F'HO8\ZO
M>;ZX)Z^8_P#.M.STV;6BUY>3MM^ZNT<GZ?Y]:S+W_C_N?^NC_P#H5=Y9QB&T
MBBSG8BC->IB:KA3BX[GP63X"&+Q=;VNL4[M=&[NU_P`3#G\+PB%OL\KB0#^,
MY!K+TG49-*O6AF8B+=B5>NUO6NX_R*XKQ(BIJQ*K\S*&;^7]*RP]5U6Z=36Y
MWYQ@:>7J&,PBY7%I66S]3H/$!SHLQ_W?_0A69X3_`-;=?[J?UJ>]D\WPDK;@
MS%4R0<\Y%0>$S@WA]%3_`-FI1C;#2CYE5JBJ9UAY]XW_``D6-:UHV;BVM\>;
MC<S,/N__`%ZS=+T$WL"W,LN(CT5!\U4KJ7^T=78C"B64(&4=N@-=Z%X'TJJD
MOJ].*CN]R,)16<8NI5Q#YJ<':*Z?UIKZG.3>%X?*/D32*X'!?D5F:?JMSI<_
MD29:%&*NGI_NUVP4*2:Y+Q1`L=Y'.N/W@PW']W_]JEAZOM6Z=36Y6;Y?#`4U
MC,%[CC:]NOJ=7%,D\2O&V0PR#4HK)T"4R:1;ECEL,N?H<5JBN*:Y9./8^FPM
M;VU&%2WQ)/[T.HI/2O./BGXP;P]HZZ993L-4OAD2(ZJUO'W;U^;#*O\`P+YO
MEHIP<Y**ZFLYJ$7)GF_Q,\8OXEUU[2VF8Z99NR1JKJRRNN[=)\O_`([_`+/^
M\U8W@OPTWBSQ+#IK2,EN%:6=X]NX(O\`=W?[3*O_``*N>Z5]*?#GPI)X5\-K
M'/&JZA=-YMR00VW^ZF>X4?7YBU>M6FL/2Y8[GF4HNO4NSY\U[1YM!UZ]TJ9M
MTEM)M5O[Z_>5O^!+M:O4_@QXK9_,\,7<BX56EL_E5?XMSI_M?>W?]]59^-'A
MPW-C!X@A7]Y:;8)S_P!,V;Y6^]_"S'^'_EI_LUXQ;74UC>V]Y;OLG@D6:-MN
M[:RMN6FK8FA9[@VZ%738^Q**YOP?XAC\3>&[74E"B5AMGC'_`"SD'WA]YL<_
M,O\`LLM='UKQI)Q;3/5BU)71YE\<?^1*L_\`L(1_^BY*\#->^?''_D2K/_L(
M1_\`HN2O`S7L8'^"SRL7_&/LFN+^*W_)-M5_[8_^CDKM*XOXK?\`)-M5_P"V
M/_HY*\JG_$B>E5_AL^:NU?5_@_\`Y$G0O^P?;_\`HM:^4.M=7:?$GQ9I]E;V
MEKJOEP6\:PQJ+>%MJJNU?X:]?%8>=5+EZ'F8:M&FVV?3](WW3]*^9_\`A:OC
M7_H,_P#DK#_\31_PM7QH3_R&?_)6'_XFN/ZA5[HZGC:=MF>IWO\`Q_7'_71_
MYUZ$/N#Z5Y;IUQ/?Z=:W5PQEN;B%))&"]69?1:[#2-<M5M4AG*Q.F%![,*VQ
M=*4H1MK8^3R#&TJ&*K1JNW,]+^5_EU[G2=Q7&^)_^0J/^N2_S-;L^NZ?;J<3
M^8V.!'S_`/6KEX(YM9U7Y^KG+E>RUCA*<HR=26B1V\08REB*<<)1:E.36SO:
MW<V;F.-?"*>6,`JC#\6!J+PIR;P>JI_6M3Q`,:),/3;_`.A"LSPG_K;K_=3^
MM$97P\Y>9-6DJ6<X>GVA;\)(Q8PMKJBAY/EAF^9L>AKT%?F4$=Q7)>(].D6X
M-ZBDQ/C?C^$U<T[Q##+`J7;JDPXW8^5O\*JO"5:$:D=>XLHK0R[%5<)7?+=W
MC?1->IT1_2N5\5LIGMDS\RJ25]C_`/JK6DUFPA3+3H_H$YKE)I9]7U'A?FD.
MU1UPM3A*4E+GDK)&O$.849X;ZK2:E*32LM;:G5>'?^0-#]6_]"-:HJO:6XM[
M6.+.=B@9JQ@$DUR3:<VSZ#!TI4</"F]TDON0ZO/M8^%6D:]K%UJ=_J&I_:)V
MW$QR1A1QM`7Y/15KT&BE"<H.\78WE",U:2N>>:7\(O#VDZI;:@ES?S2VTJRQ
MI-,NW<OW?NJO>O0Z**)SE-WD[A&$8*T58J7EG%J%C<6=RF^"XC:*09QN5AM:
MO/?^%'>&QTOM6_[_`$?_`,;KTVBG"I.'PNP2I0G\2N<AX4\"Z?X/N+F33KR]
MD%RJK(DYC8?+]T_*JGN?^^JZZEHJ92<G=L<8J*LCGO%7A2S\7Z9%8:A-/%#'
M*)5:`J&W;67^)6_O&N2_X4=X;_Y_]6_[_1__`!NO3J*N%6<%:+)E1A)W:$QQ
MBLCQ'HEMXBT2?2[MY4@GV[S$0K?*P;O_`+M;%%0FT[HMI-69YE_PH[PW_P`_
M^K?]_H__`(W1_P`*.\-_\_\`JW_?Z/\`^-UZ;16OUBK_`#&7U>E_*>9?\*.\
M-_\`/_JW_?Z/_P"-T?\`"C_#?_/_`*M_W^C_`/C=>FT4?6*W\S#ZO2_E.:L/
M"-GIT-K'#/<,MNBJ@=AEMOK\M6+OP]:W4CREWC=O0\9]:W:*7MZE[\VIRO*L
M'*+@Z:LW?YG,Q>%8E_UMP[#_`&1MK9L["VLD(@B5,]:NT43KU*GQ,,+E>$PK
MO1II/ON_O93N[9+RT>WD8JKCDCK5?3]+M]-#F%G;S,9W-FM2BI4Y*/*MCHEA
M:,JJK.*YEL_+^F02!9%*LH*MP0:Q;CPQ:N28':(]AU45T-%.%64/A=B,5@</
MBE:O%2_3T>YS,/A.('][<.P]%&VMBWTZVM%_<Q(AQC=CG\ZO44YUJD_B9GA<
2KP>%=Z--)]]W^(4445D=Y__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
